In February 2021, Signifier Medical Technologies Ltd, an innovation in the sleep-disordered breathing sector, announced that the U.S. Food and Drug Administration has approved the commercialization of a novel prescription-only device designed to alleviate snoring and moderate obstructive sleep apnea. eXciteOSA is the first of its type, a daytime treatment for snoring and moderate obstructive sleep apnea (OSA). The eXciteOSA therapy, used for only 20 minutes per day for six weeks and then twice per week thereafter for maintenance, is clinically demonstrated to enhance sleep quality by drastically lowering moderate OSA and snoring.
Tongue Retaining Device Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients